1-3 of 3
R. van der Griend
Close
Sort by
Journal Articles

Effect of Thalidomide with Melphalan and Prednisone on Health-Related Quality of Life (HRQoL) in Elderly Patients with Newly Diagnosed Multiple Myeloma: A Prospective Analysis In a Randomized Trial

S. Verelst, F. Termorshuizen, C. Uyl-de Groot, M. R Schaafsma, R. Ammerlaan, S. Wittebol, H. Sinnige, S. Zweegman, M. van Marwijk Kooy, R. van der Griend, H. Lokhorst, P. Sonneveld, P. Wijermans
Journal: Blood
Blood (2010) 116 (21): 2972.
https://doi.org/10.1182/blood.V116.21.2972.2972
Published: 2010
Journal Articles

Melphalan + Prednisone Versus Melphalan + Prednisone + Thalidomide in Induction Therapy for Multiple Myeloma in Elderly Patients: Final Analysis of the Dutch Cooperative Group HOVON 49 Study

P. Wijermans, M. Schaafsma, Y. van Norden, R. Ammerlaan, S. Wittebol, H. Sinnige, Sonja Zweegman, M. van Marwijk Kooi, R. Van der Griend, H. Lokhorst, P. Sonneveld
Journal: Blood
Blood (2008) 112 (11): 649.
https://doi.org/10.1182/blood.V112.11.649.649
Published: 2008
Journal Articles

First Analysis of HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Adriamycine, Dexamethasone (PAD) Vs VAD as Induction Treatment Prior to High Dose Melphalan (HDM) in Patients with Newly Diagnosed Multiple Myeloma (MM)

P. Sonneveld, B. van der Holt, I. G.H. Schmidt-Wolf, U. Bertsch, L. el Jarari, Hans-Jürgen Salwender, S. Zweegman, E. Vellenga, J. Schubert, I. W. Blau, GSK Jie, B. Beverloo, A. Jauch, D. Hose, R. Schaafsma, M. J. Kersten, M. Delforge, O. de Weerdt, R. van der Griend, P. W. Wijermans, Hans Martin, H. van der Velde, Henk M. Lokhorst, H. Goldschmidt
Journal: Blood
Blood (2008) 112 (11): 653.
https://doi.org/10.1182/blood.V112.11.653.653
Published: 2008